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Aims Patients with ST-segment elevation myocardial infarction (STEMI) feature thrombus-rich lesions with large necrotic
core, which are usually associated with delayed arterial healing and impaired stent-related outcomes. The use of bior-
esorbable vascular scaffolds (Absorb) has the potential to overcome these limitations owing to restoration of native
vessel lumen and physiology at long term. The purpose of this randomized trial was to compare the arterial healing
response at short term, as a surrogate for safety and efficacy, between the Absorb and the metallic everolimus-eluting
stent (EES) in patients with STEMI.
Methods
and results
ABSORB-STEMI TROFI II was a multicentre, single-blind, non-inferiority, randomized controlled trial. Patients with
STEMI who underwent primary percutaneous coronary intervention were randomly allocated 1:1 to treatment with
the Absorb or EES. The primary endpoint was the 6-month optical frequency domain imaging healing score (HS) based
on the presence of uncovered and/or malapposed stent struts and intraluminal filling defects. Main secondary endpoint
included the device-oriented composite endpoint (DOCE) according to the Academic Research Consortium defin-
ition. Between 06 January 2014 and 21 September 2014, 191 patients (Absorb [n ¼ 95] or EES [n ¼ 96]; mean age
58.6 years old; 17.8% females) were enrolled at eight centres. At 6 months, HS was lower in the Absorb arm when
compared with EES arm [1.74 (2.39) vs. 2.80 (4.44); difference (90% CI) 21.06 (21.96, 20.16); Pnon-inferiority
,0.001]. Device-oriented composite endpoint was also comparably low between groups (1.1% Absorb vs. 0%
EES). One case of definite subacute stent thrombosis occurred in the Absorb arm (1.1% vs. 0% EES; P ¼ ns).
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Conclusion Stenting of culprit lesions with Absorb in the setting of STEMI resulted in a nearly complete arterial healing which was
comparable with that of metallic EES at 6 months. These findings provide the basis for further exploration in clinically
oriented outcome trials.
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Introduction
Reperfusion therapy by means of primary percutaneous coronary inter-
vention (pPCI) is the standard of care treatment of patients with
ST-segment elevation myocardial infarction (STEMI).1 New generation
drug-eluting stents (DES) have been shown superior to BMS by redu-
cing the risk of recurrent myocardial infarction, stent thrombosis, and
target lesion revascularization.2– 6 However, in this clinical setting,
thrombotic lesions superimposed on large necrotic core-containing
plaques are common histopathological findings which have been shown
to delay arterial healing and provoke chronic inflammation. Optical co-
herence tomography imaging revealed an increased frequency of un-
covered and/or malapposed stent struts, residual thrombus, and late
pathological remodelling in lesions of STEMI compared with stable cor-
onary artery disease patients during mid- and long-term follow-up.7–9
Implantation of fully bioresorbable stents into STEMI culprit lesions
may be advantageous. Specifically, the biodegradation of the stent
struts with eventual restoration of vessel physiology, as previously
shown after Absorb bioresorbable stent implantation among patients
with stable coronary artery disease,10 may prevent the occurrence of
late events. Moreover, stents may result in a neo-cap formation11,12 as
protective layer shielding underlying large necrotic cores which are
usually located in the proximal segment of the large coronary vessels.
However, to date no head-to-head comparison has been per-
formed to assess the early phase of the arterial healing of Absorb
implantation in this thrombogenic milieu relative to that of the cur-
rent gold standard metallic DES.
Therefore, the purpose of the ABSORB-STEMI TROFI II trial was
to compare the arterial healing response between the Absorb and
the metallic everolimus-eluting stent (EES) in STEMI patients. Fur-
thermore, angiographic and clinical outcomes were compared be-
tween groups as exploratory and hypothesis-generating analyses.
Methods
Patients and study design
This is a multicentre, international, randomized, two-arm, single-blind, con-
trolled trial performed in STEMI patients (clinicaltrial.org, NCT01986803).
This is an investigator-initiated trial, sponsored by the European Cardiovas-
cular Research Institute (ECRI). Inclusion and exclusion criteria were re-
ported elsewhere.13 Briefly, the study included patients presenting with
STEMI with the following ECG criteria: at least 1 mm in two or more stand-
ard leads or at least 2 mm in two or more contiguous precordial leads or
new left bundle-branch block, within the first 24 h after the symptoms on-
set requiring emergent PCI with a vessel size ranging between 2.25 and
3.8 mm and following adequate lesion preparation. Main exclusion criteria
included cardiogenic shock, severe tortuosity, or calcification, and inad-
equate vessel size (,2.25 or .3.80 mm). All patients were randomized
1:1 to one of the two treatment arms: Absorb vs. EES (XienceTM
Expedition stent). Randomization was performed after establishment of
at least TIMI 2 flow after thrombus aspiration and/or pre-dilatation. Written
informed consent needed to be obtained in all patients prior to randomiza-
tion. Randomization was performed by dedicated web-based software. The
patients were blinded to the treatment. A total of eight centres in four
countries were involved in the trial (Supplementary material online, Appen-
dix). All centres had approval of their Medical Ethics Committee. The study
was conducted in compliance with the protocol, the Declaration of Hel-
sinki, BS EN ISO 14155 Part 1 and Part 2, and applicable local requirements.
All patients provided written informed consent. Description of the Data
and Safety Monitoring Board, Clinical Event Committee may be found in
Supplementary material online, Appendix.
Study endpoints
Study endpoints have been previously described.13 In brief, the primary
endpoint is the optical frequency domain imaging (OFDI)-derived healing
score (HS) assessed at 6 months. The HS is based on four stent-related
characteristics: presence of intraluminal mass (assigned a weight of ‘4’);
presence of both malapposed and uncovered struts (assigned a weight
of ‘3’); presence of uncovered struts alone (assigned a weight of ‘2’);
and presence of malapposed struts alone (assigned a weight of ‘1’).14,15
Precise definitions of the HS components are reported in Supplementary
material online, Appendix. In brief, a low HS indicates a favourable healing
process without intraluminal luminal defect, malapposition or uncovered
struts, etc., whereas a high HS reflects a poor healing process with rem-
nant thrombus, uncovered and/or malapposed struts.
For the OFDI endpoint analysis, stent area and derived measures are
based on the abluminal stent contour.13,16 Secondary clinical endpoints
included device-oriented composite endpoint (DOCE: composite of
cardiac death, target vessel myocardial infarction (MI), or clinically driven
target lesion revascularization, TLR) at 1, 6, and 36 months; the individual
components of DOCE; device and procedural success, all-cause death;
any myocardial infarction; non-clinically driven TLR; clinically indicated
and non-clinically driven target vessel revascularization; stent thrombosis
according to Academic Research Consortium definition17; angina status
classified according to Canadian Society of Cardiology class at 6-month
follow-up. Reinfarction is defined according to the Third Universal Def-
inition of MI as evidence of myocardial necrosis in a clinical setting con-
sistent with acute MI.18,19 Device success was defined as the implantation
of the assigned study device with a post-procedure residual stenosis
,30%.13 Procedure success was defined as device success without the
occurrence of any component of the DOCE.13 All clinical events were
adjudicated by an independent Clinical Event adjudication Committee.
Clinical follow-up was scheduled at 1, 6, 12, 24, and 36 months. Angio-
graphic follow-up was scheduled at 6 months.
Percutaneous coronary intervention procedure
Primary PCI was performed according to standard practice.2 As per
protocol, manual thrombectomy was mandatory to reduce thrombus
burden. The decision to perform pre- or post-dilatation was left to
the operator’s discretion. If these techniques were performed, specific
rules had to be followed during the procedure as well as for stent
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Figure 1 Flow chart of the study. A total of 216 patients were screened during the recruitment period. Of them 191 were included in the trial.
At 6 months, clinical follow-up was obtained in 189 patients and optical frequency domain imaging analysis was available in 171 lesions.
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sizing.13 Stent implantation was carried out following current
standards.13,20 The Absorb stent was available in the diameters of 2.5,
3.0, and 3.5 mm and in the lengths of 8, 12, 18, and 28 mm. It was re-
commended to use similar sizes for the EES (Xience XpeditionTM) stent.
Anticoagulation was achieved either by the use of bivalirudin or unfrac-
tionated heparin. The use of GPIIb/IIIa antagonists was at the operator’s
discretion. It was recommended that patients received a loading dose of
aspirin and a P2Y12 inhibitor pre-procedure, followed by dual antiplate-
let therapy for at least 12 months.
Angiographic and optical frequency domain
imaging analysis
Angiographic endpoints at 6 months included percent diameter sten-
osis, minimal lumen diameter (MLD), late lumen loss, and binary resten-
osis. All angiographic endpoints were assessed for the in-segment,
in-device, proximal, and distal region. Optical frequency domain imaging
endpoints were assessed at 6 months and included all individual compo-
nents of the HS (see above), the mean and minimal stent and diameter,
area and volume, the frequency of incomplete strut apposition including
area and volume, the percentage of uncovered struts, the mean neoin-
tima thickness, and neointimal hyperplasia area on top of the strut and
interstrut, and volume, the mean flow area and volume and intraluminal
defect area and volume.13
Optical frequency domain imaging assessment of the stented coronary
segment was performed using the TERUMO Lunawave console and the
FastView catheter. Angiography and OFDI recordings were sent to an in-
dependent Core Laboratory (Cardialysis B.V.) for off-line analysis. It was
not possible to blind the analysts to the device type based on
the characteristic appearance of Absorb and EES stent struts. Taking into
account, the difference in optical properties of cobalt chromium and poly-
lactide, OFDI analysis was performed using comparative methods.16
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1 Baseline characteristics
Absorb, N 5 95 EES, N5 96 Difference (95% CI)
Male, n (%) 73 (76.8) 84 (87.5) 210.7% [221.4%, 0.1%]
Age (years), mean+ SD 59.1+10.7 58.2+9.6 0.9 [22.0, 3.8]
Current smoking, n (%) 46 (48.4) 47 (49.5) 21.1% [215.3%, 13.2%]
Previous smoking, n (%) 22 (23.2) 22 (23.2) 0.0% [212.0%, 12.0%]
Diabetes mellitus, n (%) 18 (18.9) 14 (14.7) 4.2% [26.4%, 14.8%]
Insulin dependent, n (%) 5 (5.3) 3 (3.2) 2.1% [23.6%, 7.8%]
Non-insulin dependent, n (%) 13 (13.7) 11 (11.6) 2.1% [27.3%, 11.5%]
Hypertension, n (%) 41 (44.1) 35 (36.5) 7.6% [26.3%, 21.6%]
Hypercholesterolaemia, n (%) 60 (63.8) 55 (57.3) 6.5% [27.3%, 20.4%]
Previous stroke, n (%) 1 (1.1) 1 (1.0) 0.0% [22.9%, 2.9%]
Previous myocardial infarction, n (%) 2 (2.1) 3 (3.1) 21.0% [25.5%, 3.5%]
Previous PCI, n (%) 4 (4.2) 3 (3.1) 1.1% [24.2%, 6.4%]
Chronic obstructive pulmonary disease, n (%) 3 (3.2) 3 (3.1) 0.0% [24.9%, 5.0%]
Body mass index (kg/mm2), mean+ SD 27.0+4.1 27.7+4.2 20.7 [21.9, 0.5]
Killip class
Class 1, n (%) 90 (94.7) 93 (96.9) 22.1% [27.8%, 3.5%]
Class 2, n (%) 4 (4.2) 3 (3.1) 1.1% [24.2%, 6.4%]
Class 3, n (%) 1 (1.1) 0 (0.0) 1.1% [21.0%, 3.1%]
Class 4, n (%) 0 (0.0) 0 (0.0)
Onset of symptoms to FMC (min), mean+ SD 115+154 132+165 217 [262, 29]
Median (Q1, Q3) 52 (26, 140) 64 (31, 165)
Onset of symptoms to thrombectomy/pre-dilatation (min), mean+ SD 247+209 257+209 29 [269, 50]
Median (Q1, Q3) 177 (132, 285) 185 (130, 299)
FMC to thrombectomy/pre-dilatation (min), mean+ SD 138+145 133+84 5 [229, 39]
Median (Q1, Q3) 108 (85, 139) 115 (81, 144)
Infarct-related target lesions N ¼ 95 N ¼ 98
Right coronary artery, n (%) 44 (46.3) 44 (44.9) 1.4% [212.6%, 15.5%]
Left anterior descending artery, n (%) 34 (35.8) 41 (41.8) 26.0% [219.8%, 7.7%]
Left circumflex artery, n (%) 17 (17.9) 13 (13.3) 4.6% [25.6%, 14.9%]
Grade of perfusion (TIMI)
TIMI 0, n (%) 60 (63.2) 61 (62.9) 0.3% [213.4%, 13.9%]
TIMI 1, n (%) 3 (3.2) 3 (3.1) 0.1% [24.9%, 5.0%]
TIMI 2, n (%) 8 (8.4) 13 (13.4) 25.0% [213.8%, 3.8%]
TIMI 3, n (%) 24 (25.3) 20 (20.6) 4.6% [27.2%, 16.5%]
EES, everolimus-eluting stent; CI, confidence interval; PCI, percutaneous coronary intervention; FMC, first medical contact; TIMI, thrombolysis in myocardial infarction; Q1, first
quartile; Q3, third quartile; N refers to number of patients or lesions with data available.
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Angiographic or OFDI data from patients returning for any repeat
angiography within 14 days after the index procedure were not used
in calculation of the HS and Quantitative coronary angiography
(QCA), since the need for repeat revascularization in this period was
not related to neointimal healing but rather to an acute response of
the lesion to the procedure. This is consistent with methods used in
the resolute AC trial.21
Statistical analysis
The primary endpoint and all imaging-based (OFDI and angiography)
findings were analysed based on the as-treated population, which con-
sists of all patients whose culprit lesion have been treated with the as-
signed study device. Clinical outcomes analyses were based on the
intention-to-treat population.
Sample size was calculated assuming a mean HS of 9.0 in the Absorb
stent group with an SD of 9.4. These data were based on an OFDI
analysis of the ABSORB cohort B1 in stable patients.22 The HS of the
EES was anticipated to be similar as the one observed with the
Absorb (with similar SD) based on a historical 13 months data showing
an HS of 10.8 (SD 15.3).23 With a non-inferiority margin of 4.5 points, a
one-sided significance level (a) of 0.05 and an attrition rate of 20%, 190
patients would provide 90% power to confirm non-inferiority.
For the superiority analysis of the primary endpoint the 95% two-sided
confidence interval for the difference in the mean HS between Absorb
and EES arms, was calculated using the Students t-distribution. To elimin-
ate the influence of outliers, a sensitivity analysis was performed using the
logarithm of the HS augmented with 1. A test of normality was per-
formed; in case the normality hypothesis did not hold, the non-parametric
Wilcoxon–Mann–Whitney test was performed.
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Table 2 Procedural details
Absorb EES Difference (95% CI) P
Number of lesions 95 98
Thrombectomy 0.19
Successful thrombectomy, n (%) 77 (81.1) 72 (73.5) 7.6 [24.2, 19.4]
Unsuccessful thrombectomy, n (%) 12 (12.6) 12 (12.2) 0.4 [28.9, 9.7]
No attempt, n (%) 6 (6.3) 14 (14.3) 28.0 [216.5, 0.5]
Mode of stenting: 0.51
Direct stenting, n (%) 42 (44.2) 48 (49.0) 24.8 [218.8, 9.3]
Pre-dilatation, n (%) 53 (55.8) 50 (51.0) 4.8 [29.3, 18.8]
Maximum pressure (atm), mean+ SD 14.1+3.8 13.3+3.0 0.8 [20.6, 2.1] 0.27
Number of study devices, mean+ SD 1.2+0.4 1.1+0.4 0.0 [20.1, 0.2] 0.54
Nominal length of stent, mean+ SD 20.6+5.8 20.7+6.7 20.1 [21.8, 1.5] 0.86
Nominal diameter of stent, mean+ SD 3.25+0.30 3.12+0.37 0.13 [0.04, 0.22] 0.005
Post-dilatation performed, n (%) 48 (50.5) 25 (25.5) 25.0 [11.8, 38.3] ,0.001
Use of non-compliant balloon, n (%) 43 (89.6) 13 (52.0) 37.6 [16.2, 59.0] ,0.001
Diameter of post-dilatation balloon (mm), mean+ SD 3.51+0.34 3.29+0.62 0.22 [20.01, 0.44] 0.11
Maximum pressure (atm), mean+ SD 15.8+3.4 18.6+3.9 22.9 [24.6, 21.1] 0.002
Post-procedural grade of perfusion (TIMI) 0.50
TIMI 0, n (%) 0 (0.0) 0 (0.0)
TIMI 1, n (%) 0 (0.0) 0 (0.0)
TIMI 2, n (%) 0 (0.0) 2 (2.0) 22.0 [24.8, 0.8]
TIMI 3, n (%) 95 (100.0) 96 (98.0) 2.0 [20.8, 4.8]
Device success, n (%) 91 (95.8) 98 (100.0) 24.2 [28.2, 20.2] 0.057
Number of patients 95 96
Medication before procedure
ASA loading, n (%) 95 (100) 96 (100)
Ticagrelor, n (%) 42 (44.2) 41 (42.7) 1.5 [212.6, 15.6] 0.83
Prasugrel, n (%) 18 (18.9) 26 (27.1) 28.1 [220.0, 3.7] 0.18
Clopidogrel, n (%) 36 (37.9) 29 (30.2) 7.7 [25.7, 21.1] 0.26
Medication during procedure 0.74
Heparin only, n (%) 31 (32.6) 37 (38.5) 25.9 [219.5, 7.6]
Bivalirudin only, n (%) 7 (7.4) 9 (9.4) 22.0 [29.9, 5.8]
GP IIb/IIIa only, n (%) 1 (1.1) 2 (2.1) 21.0 [24.5, 2.5]
Heparin and bivalirudin, n (%) 18 (18.9) 13 (13.5) 5.4 [25.0, 15.8]
Heparin and GP IIb/IIIa, n (%) 37 (38.9) 35 (36.5) 2.5 [211.3, 16.2]
Bivalirudin and GP IIb/IIIa, n (%) 0.0% (0/95) 0.0% (0/96)
Procedure success, n (%) 91 (95.8) 96 (100.0) 24.2 [28.2, 20.2] 0.059
EES, everolimus-eluting stent; CI, confidence interval; atm, atmosphere; TIMI, thrombolysis in myocardial infarction.
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Continuous variables were presented as mean and standard devi-
ation or medians and interquartile ranges whenever appropriate.
The variable means were evaluated by a two-sample t-test; differences
between treatments with the corresponding 95% confidence interval
were presented. Categorical variables were summarized by frequen-
cies and percentages. Dichotomous variables were evaluated by Fish-
er’s exact test. Categorical variables with more than two categories
were evaluated by Mantel Haenszel Rank Score test.
Role of the funding source
The trial was designed by the principal investigators. The trial was spon-
sored by the ECRI and supported with unrestricted grants from
TERUMO EUROPE N.V. and ABBOTT VASCULAR. The sponsor
funded an independent data management and analysis centre (Cardialy-
sis, Rotterdam, Netherlands) for database management and all statistical
analyses. The grant givers were not involved in the conduct of the trial,
data management, data analysis, drafting of the manuscript, and did not
participate in the decision to submit the manuscript for publication. The
three PIs had full access to the study data. The corresponding author had
full responsibility for the decision to submit the report for publication.
Results
Patients
Of 2055 patients admitted with STEMI and requiring primary PCI
in the participating centres during the recruitment period, 216
were screened and 191 patients were finally included in the trial
(Figure 1) and randomly assigned to undergo treatment with Absorb
(95 patients) or EES (96 patients). Baseline clinical characteristics
were comparable between the two study groups (Table 1). Smoking
followed by dyslipidaemia were the most commonly encountered
coronary risk factors (72 and 60%, respectively). Diabetes mellitus
was found in 17% of patients. Time from symptom onset to treat-
ment, door-to-balloon time, and total ischaemia time were compar-
able between the two groups. Procedural characteristics were
presented in Table 2. Thrombectomy was attempted in 90% of
the patients and pre-dilatation in half of the population without dif-
ferences between groups. Post-dilatation was more frequently per-
formed in the Absorb arm (50.5 vs. 25.5%, P, 0.001). On average, a
total of 1.2 stents were implanted at the culprit lesion with a median
total length of 18.0 mm in both groups. Mean nominal diameter was
larger in the Absorb arm (3.25 vs. 3.12 mm; P ¼ 0.005). No dif-
ferences were observed in the antiplatelet and anticoagulation
regimens between groups. Most patients (43%) received the com-
bination of aspirin and ticagrelor loading doses before the interven-
tion. Overall, the combination of unfractionated heparin with IIb/IIIa
inhibitors accounted for 37.6% of patients, unfractionated heparin
alone 35.6%, and bivalirudin alone 8.4%. Device and procedure suc-
cess rates were both 95.8% in the Absorb arm and 100% in the EES
arm; P ¼ 0.06 and P ¼ 0.06, respectively. This difference was related
to the higher frequency of post-procedure residual stenosis in ex-
cess of .30% in the Absorb arm, 3 vs. 0 patients in the EES arm.
Pre- and post-procedural QCA analyses are presented in Ta-
ble 3. Pre-, post-procedural MLD, and acute gain were similar in
both groups. Cardiac biomarkers (peak values) were comparable
between groups (Supplementary material online, Figures SA1–SA4
and appendix). No clinical events occurred during hospitalization
in either group. At discharge, aspirin and ticagrelor constituted the
most frequently prescribed dual antiplatelet regimen (55%) fol-
lowed by aspirin and prasugrel (35%).
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Table 3 Quantitative coronary angiography (as treated analysis)
Absorb, N 5 94 EES, N5 98 Difference (95% CI) P
Pre-procedure
Lesion length (mm), mean+ SD 12.88+6.94 13.41+7.40 20.53 [22.64, 1.59] 0.62
Reference diameter (mm), mean+ SD 2.86+0.48 2.76+0.51 0.09 [20.05, 0.24] 0.91
MLD (mm), mean+ SD 0.29+0.43 0.28+0.43 0.01 [20.11, 0.14] 0.84
%DS, mean+ SD 89.5+15.1 89.9+15.4 20.4 [24.7, 4.0] 0.86
Post-procedure
Device length (mm), mean+ SD 21.41+9.86 21.16+9.77 0.26 [22.54, 3.05] 0.86
In-device reference diameter (mm), mean+ SD 2.88+0.40 2.85+0.47 0.02 [20.10, 0.15] 0.73
In-device MLD (mm), mean+ SD 2.46+0.33 2.46+0.40 20.00 [20.11, 0.10] 0.94
In-device %DS, mean+ SD 14.1+6.8 13.4+5.5 0.7 [21.0, 2.5] 0.43
In-device acute gain (mm), mean+ SD 2.16+0.52 2.21+0.56 20.04 [20.20, 0.11] 0.57
At 6 months N ¼ 84 N ¼ 89
In-device MLD (mm), mean+ SD 2.29+0.37 2.38+0.41 20.09 [20.21, 0.03] 0.13
In-device reference diameter (mm), mean+ SD 2.76+0.37 2.79+0.44 20.03 [20.15, 0.10] 0.68
In-device %DS, mean+ SD 17.3+7.4 14.5+9.3 2.8 [0.3, 5.3] 0.028
In-device late loss (mm), mean+ SD 0.17+0.24 0.08+0.28 0.09 [0.01, 0.17] 0.024
In-device binary restenosis, n (%) 0 1 (1.1) 21.1 [23.3, 1.1] 1.00
In-segment late loss (mm), mean+ SD 0.14+0.28 0.06+0.29 0.07 [20.01, 0.16] 0.09
In-segment binary restenosis, n (%) 0 1 (1.1) 21.1 [23.3, 1.1] 1.00
EES, everolimus-eluting stent; CI, confidence interval; SD, standard deviation, N refers to number of lesions with data available; MLD, minimal lumen diameter; %DS, percentage
diameter stenosis.
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Table 4 Six-month qualitative and quantitative optical coherence tomography analysis (as treated analysis)
Absorb, N 5 84 EES, N 5 87 Difference (95% CI) P
Healing score, mean+ SD 1.74+2.39 2.80+4.44 21.06 [22.14, 0.02] ,0.001* 0.053**
Healing score, median (Q1, Q3) 0.90 (0.00, 3.00) 1.04 (0.00, 3.85)
% Volume of intraluminal mass
Mean+ SD 0.0+0.0 0.0+0.0 0.0 [20.0, 0.0] 0.39
Median (Q1, Q3) 0.0 (0.0, 0.0) 0.0 (0.0, 0.0)
% Uncovered and malapposed struts
Mean+ SD 0.0+0.1 0.1+0.4 20.1 [20.2, 20.0] 0.036
Median (Q1, Q3) 0.0 (0.0, 0.0) 0.0 (0.0, 0.0)
% Covered and malapposed struts
Mean+ SD 0.6+1.2 1.5+2.9 20.9 [21.6, 20.2] 0.011
Median (Q1, Q3) 0.0 (0.0, 0.9) 0.2 (0.0, 2.3)
% Covered and apposed struts
Mean+ SD 99.4+1.0 99.1+1.8 0.2 [20.2, 0.7] 0.27
Median (Q1, Q3) 99.9 (99.2, 100.0) 100.0 (99.1, 100.0)
% Uncovered and apposed struts
Mean+ SD 0.5+1.0 0.5+1.6 20.0 [20.4, 0.4] 0.96
Median (Q1, Q3) 0.0 (0.0, 0.8) 0.0 (0.0, 0.3)
Region length (mm)
Mean+ SD 23.1+10.6 23.5+10.6 20.4 [23.6, 2.8] 0.78
Median (Q1, Q3) 18.3 (17.3, 27.4) 19.1 (17.8, 28.0)
Abluminal stent area (mm2)
Mean+ SD 8.73+1.73 8.19+2.04 0.53 [20.04, 1.11] 0.07
Median (Q1, Q3) 8.60 (7.52, 9.95) 8.05 (6.36, 9.68)
Abluminal minimal stent area (mm2)
Mean+ SD 7.30+1.69 7.04+1.88 0.26 [20.28, 0.80] 0.34
Median (Q1, Q3) 7.12 (6.00, 8.78) 7.17 (5.40, 8.29)
ISA area
Mean+ SD 0.04+0.11 0.11+0.34 20.07 [20.15, 0.01] 0.07
Median (Q1, Q3) 0.00 (0.00, 0.03) 0.00 (0.00, 0.08)
Mean intraluminal mass area (mm2)
Mean+ SD 0.00+0.00 0.00+0.00 0.00 [20.00, 0.00] 0.33
Median (Q1, Q3) 0.00 (0.00, 0.00) 0.00 (0.00, 0.00)
Mean neointimal hyperplasia area (mm2)
Mean+ SD 1.52+0.38 1.35+0.54 0.17 [0.03, 0.31] 0.018
Median (Q1, Q3) 1.47 (1.25, 1.76) 1.22 (1.01, 1.59)
Mean Lumen area (mm2)
Mean+ SD 7.06+1.79 7.02+2.01 0.04 [20.53, 0.62] 0.89
Median (Q1, Q3) 6.78 (5.81, 8.16) 6.90 (5.41, 8.40)
Minimal Lumen area (mm2)
Mean+ SD 5.40+1.75 5.53+1.87 20.13 [20.67, 0.42] 0.65
Median (Q1, Q3) 5.01 (3.98, 6.64) 5.59 (4.13, 6.96)
Mean Flow area (mm2)
Mean+ SD 7.05+1.78 7.01+2.00 0.04 [20.53, 0.61] 0.89
Median (Q1, Q3) 6.76 (5.81, 8.15) 6.90 (5.40, 8.40)
Minimal flow area (mm2)
Mean+ SD 5.40+1.75 5.53+1.87 20.13 [20.67, 0.42] 0.65
Median (Q1, Q3) 5.01 (3.98, 6.64) 5.59 (4.11, 6.96)
Abluminal stent volume (mm3)
Mean+ SD 199+90 191+96 7 [221, 35] 0.61
Median (Q1, Q3) 177 (138, 238) 168 (130, 243)
Continued
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Outcomes
Optical frequency domain imaging data are summarized in Table 4.
Representative cases are presented in Figures 2 and 3. The primary
endpoint (HS) amounted to 1.74 [2.39] in the Absorb arm vs.
2.80 [4.44] in the EES arm (difference 21.06, 90% CI 21.96 to
20.16; Pnon-inferiority , 0.001), reaching the pre-specified non-
inferiority criterion. Subsequent superiority testing resulted in a
trend favouring Absorb (Psuperiority ¼ 0.053). The difference in
HS was driven by higher frequencies of malapposed struts and un-
covered and malapposed struts in the EES compared with Absorb.
The cumulative frequency distribution curves of the HS are shown
in Figure 4.
The abluminal mean stent areas amounted to 8.73 and 8.19 mm2
in Absorb and EES, respectively (P ¼ 0.07). The neointima area was
significantly larger in the Absorb compared with EES (1.52 and
1.35 mm2 P ¼ 0.018). As a result, the mean luminal area was similar
in both groups 7.06 and 7.02 mm2 in Absorb and EES, respectively
(P ¼ 0.89). In addition, the minimum stent area (7.30 and 7.04 mm2
in Absorb and EES, respectively; P ¼ 0.34) and the minimum luminal
area (5.40 and 5.53 mm2 in Absorb and EES, respectively; P ¼ 0.65)
were similar in both groups (Supplementary material online, Figure
SB and appendix). The percentage of volume obstruction was
17.9 and 16.9% in Absorb and EES, respectively (P ¼ 0.27).
Quantitative coronary angiography data at 6-month follow-up
are summarized in Table 3. The mean in-device late lumen loss
was 0.17+ 0.24 mm in the Absorb group vs. 0.08+ 0.28 mm
in the EES arm (P ¼ 0.024). Cumulative curves of late loss
are presented in Supplementary material online, Figure SC. In-
device, binary restenosis rate was similarly low in both groups
(0% in Absorb vs. 1.1% in EES; difference 21.1% [23.3%, 1.1%];
P ¼ 1.0).
The DOCE rates were low (Absorb: 1.1% vs. Xience: 0%) at 6
months. There was no death in both groups. There was only one pa-
tient in the Absorb group suffering a subacute definite stent throm-
bosis leading to MI and clinically driven TLR. In this patient, an
inadequate matching of the vessel and device size was observed
(vessel size 1.92 mm; stent size 2.5 mm). There were in each group
one non-clinically driven TLR at 178 and 198 days. One patient in
the Xience arm underwent a non-clinically driven target vessel re-
vascularization outside of the target lesion at 198 days. In addition,
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Table 4 Continued
Absorb, N5 84 EES, N 5 87 Difference (95% CI) P
Neointimal hyperplasia volume (mm3)
Mean+ SD 35.5+20.9 31.8+19.7 3.7 [22.4, 9.8] 0.24
Median (Q1, Q3) 29.0 (23.2, 41.5) 25.8 (17.2, 40.0)
Incomplete strut apposition volume (mm3)
Mean+ SD 0.8+1.9 1.8+4.2 21.0 [22.0, 20.0] 0.048
Median (Q1, Q3) 0.0 (0.0, 0.6) 0.0 (0.0, 2.0)
Lumen volume (mm3)
Mean+ SD 160+73 164+85 24 [228, 20] 0.76
Median (Q1, Q3) 141 (108, 202) 141 (112, 191)
Flow volume (mm3)
Mean+ SD 160+73 164+85 24 [228, 20] 0.76
Median (Q1, Q3) 141 (108, 202) 141 (112, 191)
% volume obstruction
Mean+ SD 17.9+4.8 16.9+6.2 0.9 [20.7, 2.6] 0.27
Median (Q1, Q3) 17.8 (14.0, 21.2) 16.3 (12.6, 21.1)
Mean strut coverage (mm)
Mean+ SD 0.11+0.03 0.09+0.05 0.02 [0.01, 0.03] ,0.001
Median (Q1, Q3) 0.10 (0.09, 0.13) 0.07 (0.05, 0.10)
Maximal strut coverage (mm)
Mean+ SD 0.32+0.12 0.34+0.19 20.01 [20.06, 0.03] 0.56
Median (Q1, Q3) 0.30 (0.24, 0.39) 0.30 (0.21, 0.38)
ISA distance (mm)
Mean+ SD 0.39+0.15 0.32+0.16 0.07 [20.00, 0.15] 0.057
Median (Q1, Q3) 0.39 (0.29, 0.48) 0.33 (0.23, 0.41)
Mean lumen diameter (mm)
Mean+ SD 2.97+0.38 2.95+0.43 0.02 [20.11, 0.14] 0.8
Median (Q1, Q3) 2.93 (2.72, 3.22) 2.96 (2.62, 3.27)
CI, confidence interval; Q1, first quartile; Q3, third quartile; N refers to number of lesions with data available, ISA, incomplete strut apposition.
*P-value for non-inferiority test.
**P-value for superiority test.
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there were five and four non-target vessel revascularization (mostly
staged) in the Absorb arm and the Xience arm, respectively.
Most of the patients were on dual antiplatelet regimen (aspirin +
ticagrelor: 46.2% in Absorb vs. 46.9% in EES arm; P ¼ 0.92; aspirin +
prasugrel: 31.9% in Absorb vs. 37.9% in EES arm; P ¼ 0.39). At
follow-up, angina-free patients were 91.4 vs. 91.7% in the Absorb
and EES group, respectively (P ¼ 0.94).
Discussion
This is the first randomized clinical trial which investigated stenting of
culprit lesion in the setting of STEMI comparing Absorb stent with the
conventional EES. The principal findings can be summarized as follows:
(1) Stenting of culprit lesions with Absorb in the setting of STEMI
resulted in nearly complete arterial healing, which was compar-
able with that of metallic EES at 6 months.
(2) Frequency of malapposed, and both malapposed and uncovered
struts were lower in the Absorb arm, while there was no differ-
ence in intraluminal mass between groups.
(3) QCA revealed similar acute gain and MLD post-procedure. At 6
months, late lumen loss was lower in the EES arm, but binary
restenosis rate was comparably low between groups.
These findings are notable for several reasons. First, rupture pla-
ques in patients with STEMI have been shown to be prone to delay
arterial healing. Specifically, mean rate of uncovered stents appeared
to be as high as 49% in culprit lesions from STEMI when compared
with 9% in stable plaques after first-generation DES implantation.7
The advent of second-generation DES has improved the arterial
healing response. In an in vivo animal model, the use of EES when
compared with first-generation sirolimus-eluting stent was asso-
ciated with a lower incidence of uncovered struts (0.4+ 0.8 vs.
41.7+ 27.0%; P ¼ 0.004) and a minimal degree of inflammatory
Figure 2 Typical case examples of angiography and optical frequency domain imaging study in the Absorb arm (A–I) and the Xience arm (J–R).
A patient presenting with ST-segment elevation myocardial infarction was successfully treated by implantation of an Absorb stent in the mid right
coronary artery (A and B). At 6 months, the late loss was 0.13 mm (C). On optical frequency domain imaging (longitudinal view: D and cross sec-
tions: E–H), the polymeric struts were completely covered and apposed, resulting in a healing score of 0. The foldout representation of OFDI (I )
illustrates graphically the distribution of neointimal thickness per strut throughout the stent. The extent of the thickness in micron is categorized
and colour coded at the bottom of the figure. A patient presenting with ST-segment elevation myocardial infarction of RCA received a Xience
stent (J and K). The angiography and optical frequency domain imaging at 6 months showed minimal neointimal hyperplasia (angiography: L, lon-
gitudinal and cross-sectional optical frequency domain imaging: M and N–Q, foldout view: R) with excellent neointimal coverage (HS ¼ 0).
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reaction (inflammation score 0.5+0.4 vs. 2.9+ 1.4; P ¼ 0.001).24
These findings have been corroborated in humans in whom EES evi-
denced lower frequencies of uncovered struts and malapposed
struts compared with paclitaxel-eluting stent (2.3 vs. 5.2% and 2.1
vs. 5.7%, respectively; P, 0.001) as assessed by optical coherence
tomography (OCT).25 Histopathology and OCT studies have also
confirmed the superiority of EES in vascular healing process when
compared with first-generation DES.26 In a multi-imaging study,
rates of uncovered struts (1.2+ 2.3% vs. 1.0+ 2.3%) and percent-
age of stents fully covered with neointima (60.9 vs. 61.1%) appeared
to be similar in STEMI vs. stable coronary plaques at 12 months with
the use of EES.27
Secondly, EES is currently the best-in-class DES and has become
the reference in the stent comparative trials.21,28 A comprehen-
sive network meta-analysis involving 51 trials that included a total
of 52 158 randomized patients with follow-up duration ≥3 years
recently demonstrated that EES was associated with lower rates of
mortality, definite stent thrombosis, and myocardial infarction
than bare-metal stents and first-generation DES.29 In the setting
of STEMI, EES also evidenced the safest and the most efficacious
profile among their counterparts.6,30 Its safe vascular healing pro-
cess following implantation could be the basis of this clinical
advantage.
Third, OFDI was used at follow-up for the primary endpoint ana-
lysis. This intracoronary diagnostic technique is able to detect to a
nearly microscopic resolution any potential finding that could be dif-
ferent in the two groups. Up-to-date, there was only one OFDI
study that reported the arterial response head-to-head between
Absorb and EES, in stable coronary artery disease.31 At 1-year after
implantation, neointimal thickness and percentage in-device area
obstruction were comparable between groups. In the same way, un-
covered strut rate was also similar between devices (5.3 vs. 4.5%;
P ¼ 0.11). Our results are promising as they have been obtained
at a shorter follow-up period (6 months) and in the context of
high thrombogenic milieu.
Fourth, the implantation technique was guided by angiography
alone (maximum diameter assessed by on-line QCA), which corre-
sponds to routine clinical practice.
Figure 3 Case examples of suboptimal neointimal healing in the Absorb arm (A–I) and the Xience arm (J–R). A patient received an Absorb stent
in right coronary artery (A and B). The 6-month angiographic late loss was 0.16 mm (C), however, optical frequency domain imaging (longitudinal
view: D, cross-sections: E–H) showed malapposed struts (E, F, and G) and uncovered struts (G and H ). The foldout view of optical frequency
domain imaging (I ) depicted the distribution of malapposed and/or uncovered struts colour coded in red, pink, and yellow. The neointimal healing
score was 9.8. A patient received a Xience stent in the infarct-related artery (J and K). At 6-month imaging follow-up (angiography: L), there was no
restenosis but optical frequency domain imaging (M–Q) showed uncovered (N, P, and Q) and/or malapposed struts (O). The healing score of the
case was 12.2 mainly due to the high frequency of malapposed struts (R).
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In this context, the acute performance of both devices was com-
parable (Table 3). This is reassuring with respect to the initial findings
of a previous randomized trial performed in stable coronary artery
lesions where Absorb did not achieve the same acute lumen gain
as EES.32
Finally, late loss was significantly higher in the Absorb arm (0.17
vs. 0.08 mm in the EES arm; P ¼ 0.024) although this was not trans-
lated into any increase in binary restenosis rate (Absorb: 0% vs.
Xience: 1%, Table 3). The observed late lumen loss is comparable
with that of the EVERBIO II (comparison of everolimus- and
biolimus-eluting stents with everolimus-eluting bioresorbable vas-
cular scaffold stents II) randomized trial that compared the angio-
graphic performance of Absorb vs. EES vs. biolimus-eluting stent
(BES).33 The primary endpoint (late loss at 9 months) was compar-
able between groups (0.28 mm in Absorb, 0.25 mm in EES/BES
group). Of note, only 10% of patients included in EVERBIO II trial
presented with STEMI. The thicker struts of the Absorb, when com-
pared with those of EES (150 vs. 81 mm) may induce a more intense
neointimal response that leads to higher late lumen loss.34
The results of this study may have relevant clinical implications.
We have demonstrated that Absorb can deliver the same acute
and mid-term results as second-generation DES when using an ap-
propriate implantation technique.12,20 Patients presenting with STE-
MI may represent the ideal scenario for the use of Absorb.35 Culprit
lesions are frequently localized in the proximal segments of the cor-
onary artery tree.36 Therefore, restoration of physiological vasomo-
tion may have a greater effect in patients with STEMI when
compared with patients with stable coronary artery disease.
Recent study suggests that Absorb may eventually decrease the
incidence of angina during follow-up, by reducing fixed and dynamic
restenoses and by improving vasomotor responses.32 In our trial,
.90% of the patients were found to be free from angina at 6-month
follow-up. Finally, the potential advantages of implanting Absorb
(vs. other DES) in STEMI may be mostly related to the young age
of these patients. Indeed, they usually have less extensive coronary
artery disease (compared with other forms of coronary artery dis-
ease), may have a long life expectancy and thus may benefit more
from not having a permanent caging of the coronary artery. Despite
all the above, current evidence by the use of Absorb in STEMI is still
scarce and limited to few registries involving a low number of se-
lected patients.35 Recently, a propensity score matching between
Absorb (n ¼ 290), bare-metal stent (n ¼ 290), and EES (n ¼ 290)
in the context of STEMI showed a comparable incidence
of device-oriented endpoint either at 30 days or at 1 year. Of
interest, definite/probable thrombosis rate was found to be numer-
ically higher with Absorb either at 30 days (2.1% vs. 0.3%, vs. 1.0%)
or 1 year (2.4% vs. 1.4%, vs. 1.7%), when compared with EES or
bare-metal stent, respectively.37 Conversely, in our trial a very
low event rate has been observed, which may be related to refine-
ment and standardization of the implantation technique.12,20 As
mentioned above, the only episode of stent thrombosis was pre-
sumably due to an inappropriate matching of the stent to the vessel
size. Finally, another potential clinical implication regards to the ob-
served nearly complete healing at 6 months. This is reassuring for an
eventual need of antiplatelet treatment disruption or cessation be-
fore the 1-year prescription time.
Several limitations have to be acknowledged. The observed
event rate was exceedingly low. This may be related to the highly
selected population (only 10% of the STEMI patients admitted dur-
ing the recruitment period were included), due to inclusion and
exclusion criteria, need to consent in the acute phase of STEMI,
need to randomize after successful lesion preparation, and the re-
quirement of an angiographic follow-up. Thus, results cannot be
representative of more complex population suffering from STEMI.
Secondly, our study assess arterial healing at 6 months which is an
intermediate time point in which the resorption process is not
complete and the process of neointima formation in EES has not
picked yet. Six-month follow-up represents, however, the time
when the mechanical support of the Absorb stent starts to de-
crease and thus the healing should be completed at this crucial
time. A longer-term follow-up is needed to further characterize
the healing process. Third, results in HS refer to current Absorb
technology with relatively thick struts (150 mm). Therefore, these
findings cannot be extrapolated to other bioresorbable devices
with different materials or strut thickness. Fourthly, the observed
HS was lower than the assumed score in the sample size calcula-
tion (actual HS 1.74 vs. assumed HS 9.0). The original non-
inferiority margin of 4.5 was determined as 50% of the observed
HS of 9.0 in the Absorb stent in a stable angina population. If we
apply this relative non-inferiority margin to the current observa-
tion, the (post hoc) non-inferiority margin would be 1.4 (50% of
the HS in the control group: 2.80). Non-inferiority is met with
this post hoc NI margin. In addition, the distribution of observed
HS was not normal. When the log-transformation was performed,
the non-inferiority was still achieved with a P-value of ,0.001 (log-
transformed HS: 0.73+ 0.72 vs. Xience: 0.86+ 0.92, difference:
20.13). Finally, sample size does not allow us to draw any mean-
ingful conclusion regarding clinical outcomes.
In conclusion, this randomized trial demonstrated a nearly com-
plete arterial healing at 6 months after both Absorb and EES im-
plantation in the setting of STEMI. This trial provides the basis for
further exploration in clinical outcomes trials.
Figure 4 Cumulative distribution curves of the healing score be-
tween Absorb and everolimus-eluting stent arms. Healing score in
the Absorb arm was non-inferior to that of the everolimus-eluting
stent arm with a trend towards superiority.
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